You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePimozide
Accession NumberDB01100  (APRD00218)
TypeSmall Molecule
GroupsApproved
DescriptionA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Structure
Thumb
Synonyms
Halomonth
Neoperidole
Opiran
Orap
Pimozida
Pimozide
Pimozidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OrapTablet1 mg/1OralTeva Select Brands2000-06-07Not applicableUs
OrapTablet4 mgOralAa Pharma Inc1975-12-31Not applicableCanada
OrapTablet2 mg/1OralTeva Select Brands1990-09-30Not applicableUs
OrapTablet2 mg/1OralTeva Select Brands2014-10-31Not applicableUs
OrapTablet2 mgOralAa Pharma Inc1975-12-31Not applicableCanada
Orap Tab 10mgTablet10 mgOralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1983-12-311996-08-19Canada
PimozideTablet2 mgOralAa Pharma Inc2003-04-01Not applicableCanada
PimozideTablet4 mgOralAa Pharma Inc2003-04-01Not applicableCanada
PMS-pimozideTablet2 mgOralPharmascience Inc2002-10-18Not applicableCanada
PMS-pimozideTablet10 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-pimozideTablet4 mgOralPharmascience Inc2002-10-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PimozideTablet1 mg/1OralPar Pharmaceutical Inc.2014-12-01Not applicableUs
PimozideTablet2 mg/1OralPar Pharmaceutical Inc.2014-12-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NeoperidoleNot Available
OpiranNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1HIZ4DL86F
CAS number2062-78-4
WeightAverage: 461.5462
Monoisotopic: 461.227868975
Chemical FormulaC28H29F2N3O
InChI KeyYVUQSNJEYSNKRX-UHFFFAOYSA-N
InChI
InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
IUPAC Name
1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
Pharmacology
IndicationUsed for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
Structured Indications
PharmacodynamicsPimozide is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide's therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized. Pimozide also has less potential for inducing sedation and hypotension as it has more specific dopamine receptor blocking activity than other neuroleptic agents (and is therefore a suitable alternative to haloperidol).
Mechanism of actionThe ability of pimozide to suppress motor and phonic tics in Tourette's Disorder is thought to be primarily a function of its dopaminergic blocking activity. Pimozide binds and inhibits the dopamine D2 receptor in the CNS.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(3) dopamine receptorProteinyes
antagonist
HumanP35462 details
Potassium voltage-gated channel subfamily H member 2Proteinyes
inhibitor
HumanQ12809 details
CalmodulinProteinunknown
inhibitor
HumanP62158 details
Related Articles
AbsorptionGreater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Notable first-pass metabolism in the liver, primarily by N-dealkylation via the cytochrome P450 isoenzymes CYP3A and CYP1A2 (and possibly CYP2D6). The activity of the two major metabolites has not been determined.

Route of eliminationNot Available
Half life29 ± 10 hours (single-dose study of healthy volunteers).
ClearanceNot Available
ToxicityLD50 = 1100 mg/kg (rat, oral), 228 mg/kg (mouse, oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Pimozide is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Pimozide can be increased when it is combined with 1,10-Phenanthroline.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONE2-HYDROXY-1,4-NAPHTHOQUINONE may increase the arrhythmogenic activities of Pimozide.Experimental
2-mercaptobenzothiazole2-mercaptobenzothiazole may increase the arrhythmogenic activities of Pimozide.Vet Approved
2,5-Dimethoxy-4-ethylamphetaminePimozide may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Pimozide can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetaminePimozide may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetaminePimozide may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Pimozide can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-Bromo-2,5-dimethoxyamphetaminePimozide may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pimozide is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Pimozide can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Pimozide.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Pimozide.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Pimozide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Pimozide is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Pimozide.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Pimozide is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Pimozide.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pimozide.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Pimozide.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pimozide.Approved, Investigational
AlogliptinThe serum concentration of Pimozide can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Pimozide can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pimozide is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe serum concentration of Pimozide can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Pimozide.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Pimozide.Approved, Investigational
AmiodaroneThe serum concentration of Pimozide can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Pimozide.Approved
AmlodipineThe serum concentration of Pimozide can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Amobarbital.Approved, Illicit
AmorolfineAmorolfine may increase the arrhythmogenic activities of Pimozide.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Pimozide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amperozide.Experimental
AmphetaminePimozide may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BAmphotericin B may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
AmprenavirThe serum concentration of Pimozide can be increased when it is combined with Amprenavir.Approved
AN2690AN2690 may increase the arrhythmogenic activities of Pimozide.Investigational
AnagrelideAnagrelide may increase the QTc-prolonging activities of Pimozide.Approved
AnidulafunginAnidulafungin may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
Antithrombin III humanThe serum concentration of Pimozide can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Pimozide can be increased when it is combined with Apixaban.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
AprepitantThe serum concentration of Pimozide can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Pimozide can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArformoterolArformoterol may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
ArgatrobanThe serum concentration of Pimozide can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
Arsenic trioxidePimozide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherArtemether may increase the arrhythmogenic activities of Pimozide.Approved
ArticaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Articaine.Approved
AsenapinePimozide may increase the QTc-prolonging activities of Asenapine.Approved
AsunaprevirThe serum concentration of Pimozide can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Pimozide can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Pimozide.Approved
AtomoxetineThe serum concentration of Pimozide can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Pimozide can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Pimozide.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Azaperone.Vet Approved
AzelastinePimozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Pimozide is combined with Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Pimozide.Approved
BaclofenThe risk or severity of adverse effects can be increased when Pimozide is combined with Baclofen.Approved
Bafilomycin A1Bafilomycin A1 may increase the arrhythmogenic activities of Pimozide.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Barbital.Illicit
BatimastatThe serum concentration of Pimozide can be increased when it is combined with Batimastat.Experimental
BedaquilineBedaquiline may increase the QTc-prolonging activities of Pimozide.Approved
BenazeprilThe serum concentration of Pimozide can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Pimozide is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Pimozide can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pimozide.Approved
Benzoic AcidBenzoic Acid may increase the arrhythmogenic activities of Pimozide.Approved
BenzphetaminePimozide may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pimozide is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Pimozide.Approved, Vet Approved
BexaroteneThe serum concentration of Pimozide can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Pimozide can be increased when it is combined with Bi201335.Investigational
BicalutamideThe serum concentration of Pimozide can be increased when it is combined with Bicalutamide.Approved
BifonazoleBifonazole may increase the arrhythmogenic activities of Pimozide.Approved
BivalirudinThe serum concentration of Pimozide can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Pimozide can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Pimozide can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pimozide can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Pimozide.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pimozide.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pimozide is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Pimozide can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Pimozide is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pimozide is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pimozide.Approved, Investigational
BuprenorphinePimozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Pimozide can be increased when it is combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Pimozide.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pimozide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pimozide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pimozide is combined with Butamben.Approved
ButenafineButenafine may increase the arrhythmogenic activities of Pimozide.Approved
ButethalThe risk or severity of adverse effects can be increased when Pimozide is combined with Butethal.Approved, Illicit
ButoconazoleButoconazole may increase the arrhythmogenic activities of Pimozide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pimozide.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Pimozide.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pimozide.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Pimozide.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Pimozide.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Pimozide.Approved
CandicidinCandicidin may increase the arrhythmogenic activities of Pimozide.Withdrawn
CandoxatrilThe serum concentration of Pimozide can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Pimozide can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Pimozide can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Pimozide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Carbinoxamine.Approved
CarbomycinCarbomycin may increase the QTc-prolonging activities of Pimozide.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pimozide is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Pimozide.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pimozide is combined with Carisoprodol.Approved
CaspofunginCaspofungin may increase the arrhythmogenic activities of Pimozide.Approved
CeritinibThe serum concentration of Pimozide can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Pimozide.Withdrawn
CeruleninCerulenin may increase the arrhythmogenic activities of Pimozide.Approved
CetirizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pimozide is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pimozide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
ChloroxineChloroxine may increase the arrhythmogenic activities of Pimozide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorphenamine.Approved
ChlorphenterminePimozide may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorzoxazone.Approved
ChymostatinThe serum concentration of Pimozide can be increased when it is combined with Chymostatin.Experimental
CiclopiroxCiclopirox may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
CilastatinThe serum concentration of Pimozide can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Pimozide can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Pimozide can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Pimozide can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Pimozide can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pimozide.Approved, Vet Approved
CiprofloxacinThe serum concentration of Pimozide can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Pimozide.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Pimozide.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Pimozide.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Pimozide.Approved
ClemastineThe serum concentration of Pimozide can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pimozide is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Pimozide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Pimozide is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Pimozide.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Pimozide.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Pimozide.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pimozide.Approved, Illicit
ClotrimazoleThe serum concentration of Pimozide can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Pimozide.Approved
CobicistatThe serum concentration of Pimozide can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Pimozide.Approved
CocaineThe serum concentration of Pimozide can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pimozide.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Pimozide.Approved
ConivaptanThe serum concentration of Pimozide can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pimozide.Approved
CordycepinCordycepin may increase the arrhythmogenic activities of Pimozide.Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Pimozide.Approved
CyclizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pimozide.Approved
CyclosporineThe serum concentration of Pimozide can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Pimozide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Pimozide can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Pimozide can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Pimozide.Approved
DalfopristinThe serum concentration of Pimozide can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Pimozide can be increased when it is combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Pimozide is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Pimozide.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pimozide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pimozide.Investigational
DarunavirThe serum concentration of Pimozide can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Pimozide can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Pimozide.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Pimozide.Approved
Decanoic AcidDecanoic Acid may increase the arrhythmogenic activities of Pimozide.Experimental
DeferasiroxThe serum concentration of Pimozide can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Pimozide.Approved
DelavirdineThe serum concentration of Pimozide can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Pimozide is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Pimozide.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Pimozide.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pimozide.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Pimozide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pimozide.Approved, Vet Approved
DextroamphetaminePimozide may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pimozide.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pimozide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Pimozide.Approved, Illicit, Vet Approved
DiethylpropionPimozide may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pimozide.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Pimozide is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Pimozide.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pimozide.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Pimozide can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Pimozide.Illicit
DiltiazemThe serum concentration of Pimozide can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Pimozide is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Pimozide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pimozide.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Pimozide.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Pimozide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Pimozide.Approved, Investigational
DofetilideDofetilide may increase the QTc-prolonging activities of Pimozide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Pimozide.Approved
DomperidonePimozide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Pimozide is combined with Doramectin.Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Pimozide.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Pimozide.Approved, Investigational
DoxycyclineThe serum concentration of Pimozide can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pimozide is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved, Illicit
DronedaroneThe serum concentration of Pimozide can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pimozide is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pimozide.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pimozide.Approved
EcabetThe serum concentration of Pimozide can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Pimozide is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pimozide is combined with ECGONINE METHYL ESTER.Experimental
EconazoleEconazole may increase the arrhythmogenic activities of Pimozide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Pimozide is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Pimozide can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Pimozide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleEfinaconazole may increase the arrhythmogenic activities of Pimozide.Approved
ElafinThe serum concentration of Pimozide can be increased when it is combined with Elafin.Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Pimozide.Approved, Investigational
EliglustatPimozide may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilThe serum concentration of Pimozide can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Pimozide can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Pimozide can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pimozide.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Pimozide is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Pimozide can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Pimozide.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pimozide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pimozide.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pimozide.Approved
EribulinEribulin may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Pimozide.Approved, Investigational
ErythromycinThe serum concentration of Pimozide can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pimozide.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Pimozide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Pimozide is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Pimozide.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Pimozide.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Pimozide.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pimozide.Approved
EthanolPimozide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pimozide.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pimozide.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pimozide is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pimozide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pimozide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Pimozide.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Pimozide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Pimozide can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Pimozide.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Pimozide.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Pimozide.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Pimozide.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Pimozide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pimozide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pimozide.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Pimozide.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Pimozide.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Pimozide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Pimozide is combined with Flibanserin.Approved
FluconazoleFluconazole may increase the arrhythmogenic activities of Pimozide.Approved
FlucytosineFlucytosine may increase the arrhythmogenic activities of Pimozide.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Flunitrazepam.Approved, Illicit
FluoxetineFluoxetine may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Pimozide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pimozide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pimozide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Pimozide.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Pimozide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
FosamprenavirThe serum concentration of Pimozide can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pimozide can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Pimozide.Approved
FosinoprilThe serum concentration of Pimozide can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Pimozide can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Pimozide is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Pimozide.Approved, Investigational
Fusidic AcidThe serum concentration of Pimozide can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pimozide.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pimozide is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Pimozide can be increased when it is combined with Gabexate.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Pimozide.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Pimozide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pimozide is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Pimozide.Approved, Investigational
GeldanamycinThe serum concentration of Pimozide can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Pimozide.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Pimozide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Pimozide is combined with Glutethimide.Approved, Illicit
Glycerol PhenylbutyrateThe serum concentration of Pimozide can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GlyphosateGlyphosate may increase the arrhythmogenic activities of Pimozide.Experimental
GM6001The serum concentration of Pimozide can be increased when it is combined with GM6001.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Pimozide.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Pimozide.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Pimozide.Withdrawn
GriseofulvinGriseofulvin may increase the arrhythmogenic activities of Pimozide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Pimozide is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pimozide.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Pimozide.Approved
HaloproginHaloprogin may increase the arrhythmogenic activities of Pimozide.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Pimozide is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Pimozide is combined with Heroin.Approved, Illicit
HexetidineHexetidine may increase the arrhythmogenic activities of Pimozide.Approved
HexobarbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Hexobarbital.Approved
HirulogThe serum concentration of Pimozide can be increased when it is combined with Hirulog.Experimental
HistrelinHistrelin may increase the QTc-prolonging activities of Pimozide.Approved
HydrocodonePimozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Pimozide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pimozide.Approved, Illicit
Hydroxyamphetamine hydrobromidePimozide may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Pimozide.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Pimozide.Approved
IdelalisibThe serum concentration of Pimozide can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Pimozide can be increased when it is combined with idraparinux.Investigational
IloperidoneThe serum concentration of Pimozide can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Pimozide can be increased when it is combined with Imatinib.Approved
ImidaprilThe serum concentration of Pimozide can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Pimozide.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pimozide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Pimozide.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Pimozide.Approved
IndinavirThe serum concentration of Pimozide can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Pimozide.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Pimozide.Approved, Investigational
IsavuconazoniumThe serum concentration of Pimozide can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pimozide.Approved
IsoconazoleIsoconazole may increase the arrhythmogenic activities of Pimozide.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
IsoflurophateThe serum concentration of Pimozide can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Pimozide can be increased when it is combined with Isoniazid.Approved
IsradipineThe serum concentration of Pimozide can be increased when it is combined with Isradipine.Approved
ItraconazoleItraconazole may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Pimozide.Approved
IvacaftorThe serum concentration of Pimozide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Pimozide.Approved, Vet Approved
IxazomibThe serum concentration of Pimozide can be increased when it is combined with Ixazomib.Approved
JosamycinJosamycin may increase the QTc-prolonging activities of Pimozide.Approved
KetamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Pimozide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketobemidone.Approved
KetoconazoleKetoconazole may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
KitasamycinKitasamycin may increase the QTc-prolonging activities of Pimozide.Experimental
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Pimozide.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Pimozide.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Pimozide.Approved, Investigational
LapatinibThe serum concentration of Pimozide can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Pimozide.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Pimozide.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Pimozide.Approved
LepirudinThe serum concentration of Pimozide can be increased when it is combined with Lepirudin.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Pimozide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pimozide.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Pimozide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Pimozide can be decreased when used in combination with Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pimozide is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pimozide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pimozide.Approved
LidocaineThe metabolism of Pimozide can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Pimozide can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Pimozide.Approved, Investigational
LisdexamfetaminePimozide may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Pimozide can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Pimozide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pimozide is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Pimozide can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Pimozide.Approved
LopinavirThe serum concentration of Pimozide can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pimozide.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pimozide.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Pimozide.Approved
LovastatinThe serum concentration of Pimozide can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pimozide.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Pimozide is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Pimozide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Pimozide can be increased when combined with Lumacaftor.Approved
LumefantrinePimozide may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Pimozide can be increased when it is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Pimozide.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Pimozide.Approved
MeclizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Pimozide.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pimozide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Melperone.Approved
MephedronePimozide may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePimozide may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pimozide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pimozide.Approved, Illicit
MequitazinePimozide may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pimozide.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Pimozide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pimozide is combined with Methadyl Acetate.Approved, Illicit
MethamphetaminePimozide may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Pimozide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Pimozide is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pimozide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pimozide.Approved
MethotrimeprazineThe serum concentration of Pimozide can be increased when it is combined with Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pimozide.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pimozide.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Pimozide.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimozide.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pimozide.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pimozide.Approved
MetyrosinePimozide may increase the sedative activities of Metyrosine.Approved
MevastatinMevastatin may increase the arrhythmogenic activities of Pimozide.Experimental
MexiletineThe metabolism of Pimozide can be decreased when combined with Mexiletine.Approved
MicafunginMicafungin may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
MiconazoleMiconazole may increase the arrhythmogenic activities of Pimozide.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Pimozide.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Pimozide.Approved
MiltefosineMiltefosine may increase the arrhythmogenic activities of Pimozide.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Pimozide.Approved
MirtazapinePimozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Pimozide can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Pimozide.Approved, Investigational
MMDAPimozide may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pimozide.Approved
ModafinilThe serum concentration of Pimozide can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Pimozide can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Molindone.Approved
MonensinMonensin may increase the arrhythmogenic activities of Pimozide.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Pimozide.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pimozide.Approved, Investigational
MyxothiazolMyxothiazol may increase the arrhythmogenic activities of Pimozide.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Pimozide can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Pimozide.Approved
NafamostatThe serum concentration of Pimozide can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Pimozide can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may increase the arrhythmogenic activities of Pimozide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pimozide.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Pimozide.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Pimozide.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pimozide.Approved, Investigational
NatamycinNatamycin may increase the arrhythmogenic activities of Pimozide.Approved
NCX 4016The serum concentration of Pimozide can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe serum concentration of Pimozide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pimozide can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Pimozide can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Pimozide can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Pimozide can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Pimozide.Approved
NilotinibThe serum concentration of Pimozide can be increased when it is combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Pimozide.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Nitrazepam.Approved
NitroaspirinThe serum concentration of Pimozide can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Pimozide is combined with Nitrous oxide.Approved, Vet Approved
NitroxolineNitroxoline may increase the arrhythmogenic activities of Pimozide.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Pimozide.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pimozide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Pimozide.Approved
NystatinNystatin may increase the arrhythmogenic activities of Pimozide.Approved, Vet Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Pimozide.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
OlaparibThe serum concentration of Pimozide can be increased when it is combined with Olaparib.Approved
OleandomycinOleandomycin may increase the QTc-prolonging activities of Pimozide.Vet Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pimozide.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Pimozide can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Pimozide.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Pimozide.Approved
OpiumThe risk or severity of adverse effects can be increased when Pimozide is combined with Opium.Approved, Illicit
OrphenadrinePimozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pimozide is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Pimozide can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Pimozide can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pimozide.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxetacaine.Investigational
OxiconazoleOxiconazole may increase the arrhythmogenic activities of Pimozide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pimozide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pimozide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Pimozide.Approved, Vet Approved
pafuramidinepafuramidine may increase the arrhythmogenic activities of Pimozide.Investigational
PalbociclibThe serum concentration of Pimozide can be increased when it is combined with Palbociclib.Approved
PaliperidonePimozide may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
ParaldehydePimozide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pimozide.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Pimozide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Pimozide.Approved
Peginterferon alfa-2bThe serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the arrhythmogenic activities of Pimozide.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pimozide.Approved, Vet Approved
PentobarbitalThe metabolism of Pimozide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PerazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Pimozide.Approved
PerindoprilThe serum concentration of Pimozide can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Pimozide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pimozide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pimozide.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pimozide.Approved
PhenobarbitalThe metabolism of Pimozide can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pimozide is combined with Phenoxyethanol.Approved
PhenterminePimozide may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Pimozide can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Pimozide can be increased when it is combined with Phosphoramidon.Experimental
PipamperoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Pimozide can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Pimozide is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Pimozide.Approved
PizotifenThe risk or severity of adverse effects can be increased when Pimozide is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Pimozide.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Pimozide.Approved
PosaconazolePosaconazole may increase the arrhythmogenic activities of Pimozide.Approved, Investigational, Vet Approved
PramipexolePimozide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Pimozide.Approved
PrazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Pimozide.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Pimozide.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Pimozide.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pimozide.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pimozide.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Pimozide.Approved
PrimidoneThe metabolism of Pimozide can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Pimozide can be increased when it is combined with Prinomastat.Investigational
ProcainamideProcainamide may increase the QTc-prolonging activities of Pimozide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pimozide.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pimozide.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pimozide.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Pimozide.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Pimozide.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Pimozide.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pimozide.Approved, Vet Approved
PropofolThe serum concentration of Pimozide can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Pimozide.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Pimozide.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Pimozide.Approved
PSD502The risk or severity of adverse effects can be increased when Pimozide is combined with PSD502.Investigational
PseudoephedrinePimozide may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Quazepam.Approved, Illicit
QuetiapinePimozide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Pimozide.Approved
QuinaprilThe serum concentration of Pimozide can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Pimozide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Pimozide.Approved
QuinupristinThe serum concentration of Pimozide can be increased when it is combined with Quinupristin.Approved
RacecadotrilThe serum concentration of Pimozide can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Pimozide is combined with Raclopride.Investigational
RadicicolRadicicol may increase the arrhythmogenic activities of Pimozide.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Pimozide is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Pimozide can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Pimozide.Approved
RanolazineThe serum concentration of Pimozide can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pimozide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pimozide.Approved
RemikirenThe serum concentration of Pimozide can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pimozide.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Pimozide.Approved
RifabutinThe metabolism of Pimozide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pimozide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pimozide can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pimozide.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Pimozide.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pimozide is combined with Ritanserin.Investigational
RitobegronPimozide may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Pimozide can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Pimozide can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pimozide.Approved
RolapitantThe serum concentration of Pimozide can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Pimozide.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Romifidine.Vet Approved
RopinirolePimozide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pimozide.Approved
RotigotinePimozide may increase the sedative activities of Rotigotine.Approved
RoxithromycinRoxithromycin may increase the QTc-prolonging activities of Pimozide.Approved, Withdrawn
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pimozide.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pimozide is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Pimozide is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
Salicylhydroxamic AcidSalicylhydroxamic Acid may increase the arrhythmogenic activities of Pimozide.Experimental
Salicylic acidSalicylic acid may increase the arrhythmogenic activities of Pimozide.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Pimozide.Approved
SaquinavirThe serum concentration of Pimozide can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Pimozide can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pimozide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Pimozide.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Pimozide.Approved
SertaconazoleSertaconazole may increase the arrhythmogenic activities of Pimozide.Approved
SertindoleThe risk or severity of adverse effects can be increased when Pimozide is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Pimozide.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
SildenafilThe serum concentration of Pimozide can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Pimozide.Approved
SiltuximabThe serum concentration of Pimozide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pimozide can be increased when it is combined with Simeprevir.Approved
SinefunginSinefungin may increase the arrhythmogenic activities of Pimozide.Experimental
SirolimusSirolimus may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
SitagliptinThe serum concentration of Pimozide can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Pimozide.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Pimozide.Approved
SolithromycinSolithromycin may increase the QTc-prolonging activities of Pimozide.Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Pimozide.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Pimozide.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Pimozide.Experimental
SpiraprilThe serum concentration of Pimozide can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Pimozide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Pimozide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.Approved, Investigational
SulconazoleSulconazole may increase the arrhythmogenic activities of Pimozide.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Pimozide.Approved
SulfisoxazoleThe serum concentration of Pimozide can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Pimozide.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
SuvorexantPimozide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Pimozide.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Pimozide.Approved
TandospironeThe risk or severity of adverse effects can be increased when Pimozide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pimozide is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Pimozide.Experimental
TavaboroleTavaborole may increase the arrhythmogenic activities of Pimozide.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pimozide.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pimozide.Approved
TelaprevirThe serum concentration of Pimozide can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Pimozide.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Pimozide.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pimozide.Approved
TemocaprilThe serum concentration of Pimozide can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Pimozide.Approved
TenofovirThe metabolism of Pimozide can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineTerbinafine may increase the arrhythmogenic activities of Pimozide.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pimozide.Approved
TerconazoleTerconazole may increase the arrhythmogenic activities of Pimozide.Approved
TeriflunomideThe serum concentration of Pimozide can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pimozide.Approved
TetracaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetrodotoxin.Investigational
ThalidomidePimozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Pimozide can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pimozide.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pimozide.Approved
ThiorphanThe serum concentration of Pimozide can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThiothixene may increase the QTc-prolonging activities of Pimozide.Approved
ThymolThymol may increase the arrhythmogenic activities of Pimozide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Pimozide can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Pimozide can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Pimozide.Approved
TioconazoleTioconazole may increase the arrhythmogenic activities of Pimozide.Approved
TipranavirThe serum concentration of Pimozide can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Pimozide.Approved
TocilizumabThe serum concentration of Pimozide can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Pimozide is combined with Tolcapone.Approved, Withdrawn
TolnaftateTolnaftate may increase the arrhythmogenic activities of Pimozide.Approved, Vet Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Pimozide.Approved
TopiramateThe risk or severity of adverse effects can be increased when Pimozide is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Pimozide.Approved, Investigational
ToremifeneToremifene may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pimozide.Approved, Investigational
TrandolaprilThe serum concentration of Pimozide can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pimozide.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Pimozide.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pimozide.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pimozide.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pimozide.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
TrimetrexateTrimetrexate may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
TrimipramineTrimipramine may increase the QTc-prolonging activities of Pimozide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pimozide.Approved, Vet Approved
TroleandomycinTroleandomycin may increase the QTc-prolonging activities of Pimozide.Approved
TylosinTylosin may increase the QTc-prolonging activities of Pimozide.Vet Approved
UbenimexThe serum concentration of Pimozide can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Pimozide is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Pimozide can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Pimozide.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Pimozide.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pimozide.Approved, Investigational
VandetanibPimozide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Pimozide.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Pimozide.Approved
VemurafenibThe serum concentration of Pimozide can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Pimozide.Approved
VenlafaxineThe serum concentration of Pimozide can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Pimozide can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Pimozide is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Pimozide.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pimozide.Approved
VildagliptinThe serum concentration of Pimozide can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Pimozide.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Pimozide.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Pimozide.Approved
VoriconazoleVoriconazole may increase the arrhythmogenic activities of Pimozide.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Pimozide.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Pimozide is combined with Vortioxetine.Approved
XimelagatranThe serum concentration of Pimozide can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Xylazine.Vet Approved
Ym150The serum concentration of Pimozide can be increased when it is combined with Ym150.Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pimozide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Pimozide.Approved
ZileutonThe serum concentration of Pimozide can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Pimozide.Withdrawn
ZiprasidoneThe serum concentration of Pimozide can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pimozide.Approved, Investigational
ZolpidemPimozide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Pimozide is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pimozide is combined with Zotepine.Approved
ZuclopenthixolPimozide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
  • Take without regard to meals.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AG02
AHFS Codes
  • 28:16.08.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (29 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9685
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6639
P-glycoprotein inhibitor IInhibitor0.8842
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.7255
CYP450 2C9 substrateNon-substrate0.7829
CYP450 2D6 substrateNon-substrate0.9112
CYP450 3A4 substrateSubstrate0.6579
CYP450 1A2 substrateInhibitor0.9062
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.686
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9217
Ames testNon AMES toxic0.7856
CarcinogenicityNon-carcinogens0.9348
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6925
hERG inhibition (predictor II)Inhibitor0.9192
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg/1
TabletOral2 mg
TabletOral2 mg/1
TabletOral4 mg
TabletOral10 mg
Prices
Unit descriptionCostUnit
Orap 1 mg tablet1.22USD tablet
Orap 2 mg tablet1.17USD tablet
Orap 4 mg Tablet0.47USD tablet
Apo-Pimozide 4 mg Tablet0.43USD tablet
Apo-Pimozide 2 mg Tablet0.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point214-218 °CPhysProp
water solubility10 mg/L (at 25 °C)MERCK INDEX (1996)
logP6.30HANSCH,C ET AL. (1995)
pKa8.63EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00173 mg/mLALOGPS
logP6.36ALOGPS
logP5.83ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)12.9ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.58 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity132.21 m3·mol-1ChemAxon
Polarizability50.04 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-4890100000-ff909df45204eac82c46View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylbutylamine
  • Benzimidazole
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • 4-aminopiperidine
  • Piperidine
  • N-substituted imidazole
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Silva MR, Bernardi MM, Cruz-Casallas PE, Felicio LF: Pimozide injections into the Nucleus accumbens disrupt maternal behaviour in lactating rats. Pharmacol Toxicol. 2003 Jul;93(1):42-7. [PubMed:12828573 ]
  4. Muscat R, Sampson D, Willner P: Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry. 1990 Aug 1;28(3):223-30. [PubMed:2378927 ]
  5. Zarrindast MR, Heidari MR: On the mechanisms by which theophylline changes core body temperature in mice. Eur J Pharmacol. 1994 May 12;257(1-2):13-20. [PubMed:8082693 ]
  6. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  8. Murphy LL, Adrian BA, Kohli M: Inhibition of luteinizing hormone secretion by delta9-tetrahydrocannabinol in the ovariectomized rat: effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists. Steroids. 1999 Sep;64(9):664-71. [PubMed:10503726 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Kang J, Wang L, Cai F, Rampe D: High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol. 2000 Mar 31;392(3):137-40. [PubMed:10762666 ]
  2. Osypenko VM, Degtiar VIe, Naid'onov VG, Shuba IaM: [Blockade of HERG K+ channels expressed in Xenopus oocytes by antipsychotic agents]. Fiziol Zh. 2001;47(1):17-25. [PubMed:11296551 ]
  3. Shuba YM, Degtiar VE, Osipenko VN, Naidenov VG, Woosley RL: Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol. 2001 Jul 1;62(1):41-9. [PubMed:11377395 ]
  4. Kang J, Chen XL, Rampe D: The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel. Biochem Biophys Res Commun. 2001 Aug 24;286(3):499-504. [PubMed:11511086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Papadopoulos V, Brown AS, Hall PF: Calcium-calmodulin-dependent phosphorylation of cytoskeletal proteins from adrenal cells. Mol Cell Endocrinol. 1990 Dec 3;74(2):109-23. [PubMed:1965307 ]
  2. Wang XB, Sato N, Greer MA, Greer SE, McAdams S: Role of extracellular calcium and calmodulin in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells. Acta Endocrinol (Copenh). 1990 Aug;123(2):218-24. [PubMed:2120879 ]
  3. Strobl JS, Kirkwood KL, Lantz TK, Lewine MA, Peterson VA, Worley JF 3rd: Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res. 1990 Sep 1;50(17):5399-405. [PubMed:2386945 ]
  4. Cimino M, Weiss B: Characteristics of the binding of phenoxybenzamine to calmodulin. Biochem Pharmacol. 1988 Jul 15;37(14):2739-45. [PubMed:3134891 ]
  5. Mody I, Baimbridge KG, Miller JJ: Blockade of tetanic- and calcium-induced long-term potentiation in the hippocampal slice preparation by neuroleptics. Neuropharmacology. 1984 Jun;23(6):625-31. [PubMed:6146939 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  2. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23